The chemotherapy resistance and toxicity of chemotherapy are major problems in breast cancer treatment. However, candidate biomarkers for predicting clinical outcomes and better prognosis remain lacking. | Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxelbased chemotherapy in breast cancer patients